Pfizer TodayPFEPfizer$23.75 +0.15 (+0.64%) 52-Week Range$20.92▼$30.43Dividend Yield7.24%P/E Ratio12.63Price Target$28.12Add to WatchlistIn the United States' healthcare sector, a new growth theme is emerging that nearly all companies want to capitalize on. Like artificial intelligence for technology stocks, weight loss drug manufacturing and distribution businesses are all the hype for this new growth wave taking over the industry. That said, there are two ways for businesses to capitalize on this opportun ...

Investors once speculated that Pfizer might consider acquiring Viking.Weight loss drugs have represented an enormous growth area for biotech and pharma companies over the past couple of years. Pharma giants Eli Lilly and Novo Nordisk dominate the market with their drugs and have brought in billions of dollars in revenue as demand skyrocketed. In fact, last year demand was so high -- surpassing supply at certain points -- that these drugs were on the U.S. Food and Drug Administration's drug shortage list.Sin ...

Oracle ( ORCL ) has confirmed it will run TikTok US; is naming two CEOs to accommodate the handoffFed Governor Stephen Miran, the 'lone dot' on the Fed Dot Plot, said that Fed rates should be 2.00% lower in his first public speech post-FOMC.The index went from 6,200 to 6,300 in just 15 trading days. From there, it went to 6,400 in 17, 6,500 in 13, and 6,600 in 12. If it were to hit 6,700 today, it would have done so in just 6 trading days.The S&P 500 is sitting just off intraday highs, inching closer and cl ...

The telehealth platform is growing quickly but is in the middle of a legal battle.Shares of Hims & Hers (HIMS 1.49%) stock sank 17% this week, according to data from S&P Global Market Intelligence. The telehealth platform is delivering huge revenue growth but is at risk of a legal battle with weight loss drugmakers. Shares of the stock are down 25% from all-time highs but are up 400% in the past five years due to the platform's fast growth.Here's why the stock sank this week.Fast growth but a looming lawsui ...

文章核心观点 - 诺和诺德股价虽在2024年大幅下跌，但未来不仅会恢复，还会大幅上涨 [1] 行业情况 - 减肥药物精准瞄准美国庞大市场，美国肥胖问题未改善，1990 - 2022年肥胖率从略超21%升至近44% [2] - 2022年全球超10亿人受肥胖影响，2024年全球减肥药物销售额首次超300亿美元，分析师预计销售额将大幅增长 [3] - 摩根士丹利将2030年减肥药物销售预测从770亿美元上调至至少1050亿美元，最高可达1440亿美元，未来六年多至少有三倍增长潜力 [4] 公司情况 - 诺和诺德和礼来是美国减肥药物市场的两大主导企业，维京治疗公司正在开发后期阶段的治疗方法且试验效果良好 [5] - 在美国和欧盟等大司法管辖区，药物获批需要时间，诺和诺德的Wegovy已成为肥胖治疗的首选药物，即使份额被竞争对手抢占，仍能在快速增长的市场中占据重要份额 [6]